CV301

Immunotherapy candidate for multiple cancers

PHASE 2


CV301 is a novel immunotherapy candidate that targets two tumor-associated antigens, CEA and MUC-1, which are overexpressed in major cancer types. Similar to PROSTVAC, CV301 uses a prime/boost dosing schedule albeit using MVA-BN as a primer, followed by multiple fowlpox boosts, and encodes the TRICOM costimulatory molecules.

The development of CV301 focuses on combination treatments with other immune-modulating agents such as checkpoint inhibitors as the understanding in the disease pathophysiology evolves with respect to the immune system. The options for modulation of the immune system for cancer treatment are increasing and the development of CV301 will also evolve to take advantage of these options. From a functional standpoint, CV301 has the potential to be combined with most cancer immune modulators. We believe CV301 equips the immune system with the ability to seek out and destroy tumor cells.

Preclinical data shows that CV301 upregulates PD-L1 by mounting an immune response against a tumor target. The upregulation of PD-L1 is a marker indicating the tumor is under attack from T-cells, presenting an opportunity for a greater response in patients who might otherwise not benefit from treatment with a checkpoint inhibitor alone.

CEA and MUC-1 overexpression in selected cancers

  CEA+ MUC-1+
Lung cancer 70% 80%
Bladder cancer 60% - 75% >90%
Colorectal cancer >90% >90%
Breast cancer 50% >90%
Pancreatic cancer >95% >95%